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Recent studies have shown that rebamipide, which suppresses reactive oxygen species, prevents
chemoradiotherapy-induced oral mucositis in patients with head and neck cancers. However, anticancer
action of radiotherapy and chemotherapy is believed to be partially associated with generation of
reactive oxygen species. The aim of this study was to determine whether rebamipide interferes with the
antitumor action of radiotherapy and chemotherapy. The effect of rebamipide on tumor cell growth was
investigated using a human oral squamous carcinoma cell line, HSC-2, in vitro and in vivo. Rebamipide
showed no signiﬁcant effect on cell or tumor growth in HSC-2 tumor-bearing nude mice. Inﬂuences of
rebamipide on the antitumor action of radiotherapy and of chemotherapy with cisplatin or docetaxel
were investigated using the same animal model. In radiotherapy, the tumor was treated with 2.5 Gy of X-
rays for 5 days, and rebamipide (300 mg/kg p.o.) was administered during irradiation periods. In
chemotherapy, tumor-bearing mice were treated once with cisplatin (8 mg/kg, i.v.) or docetaxel (15 mg/
kg i.v.) and rebamipide (300 mg/kg p.o.) was administered for 5 days following the antitumor drug
treatment. Rebamipide did not interfere with the antitumor action of radiotherapy and chemotherapy.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rebamipide (2-{4-chlorobenzoylamino-3-[2(1H)-quinolinon-4-
yl]} propionic acid, CAS 11911-87-6, MW 370.79) was discovered
by in vivo screening for agents that accelerated healing of acetic
acid-induced gastric ulcer in rats (1). It has been widely used for
gastric mucosal protection, healing of gastric ulcer, and treatment
of gastritis in East Asian countries (2, 3). The precise mode of action
is still under evaluation, but rebamipide has various pharmaco-
logical effects, including increasing the production of gastric mucus
(4) and prostaglandins (5, 6), inhibiting superoxide anion produc-
tion from activated neutrophils (7, 8), scavenging hydroxyl radicalsrug Discovery, Otsuka Phar-
Tokushima, 771-0192, Japan.
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).(9, 10), suppressing gastric mucosal inﬂammation (11, 12), and
upregulating growth factors and their receptor expressions (13, 14).
Oral mucositis is a common and severe side effect in patients
with head and neck cancers undergoing chemotherapy and radio-
therapy (15). It is frequently associated with severe pain and difﬁ-
culties in eating and swallowing (16) and may even affect
continuation of anticancer therapy. To prevent oral mucositis,
various agents have been developed and tested in preclinical and
clinical studies, but no effective and tolerated medications have
been established to date (17). Generation of reactive oxygen species
(ROS) by radiation and chemotherapy directly injures DNA, causing
strand breakage resulting in clonogenic death of basal epithelial
cells (18). Radiation, chemotherapy, and ROS also activate the nu-
clear factor kappa B (NF-kB) pathway, inducing the production of
proinﬂammatory cytokines and chemokines and resulting in
mucosal inﬁltration of inﬂammatory cells (18). Translocation of oral
bacteria from injured epithelium also triggers inﬁltration and
activation of inﬂammatory cells (18).r B.V. on behalf of Japanese Pharmacological Society. This is an open access article
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logical activitiesof rebamipide, thedrughasbeen suggestedas anovel
strategy to prevent and/or treat oral mucositis. Rebamipide has
recently been reported to prevent chemoradiotherapy-induced oral
mucositis in patients with head and neck cancers (19). We also
recently established a quantitative and reproducible rat glossitis
model induced by single X-ray irradiation of the snout (20) and found
that intraoral administration of submicronized rebamipide suspen-
sion prevented tongue injury (21). However, it may be of concern
whether rebamipide affects the antitumor effect of radiotherapy and
chemotherapy. In this study,we investigated theeffects of rebamipide
administered in combination with radiotherapy or chemotherapy to
human oral squamous carcinoma cell line-bearing nude mice.
2. Materials and methods
2.1. Chemicals
Cisplatin (CDDP) and docetaxel (DOC) were obtained from Nip-
pon Kayaku Co., Ltd. (Tokyo) and Sanoﬁ K.K. (Tokyo), respectively.
Rebamipide is a product of Otsuka Pharmaceutical Co, Ltd. (Tokyo).
2.2. Cell lines and cell culture
Four human oral squamous carcinoma cell lines, HSC-2
(JCRB0622), HSC-3 (JCRB0623), Ca9-22 (JCRB0625), and HO-1-u-1
(JCRB0828) were obtained from the Health Science Research Re-
sources Bank (Osaka). HSC-2 and -3 cells were grown in minimum
essential medium (MEM) containing 10% fetal bovine serum (FBS)
(Life Technologies Japan Ltd., Tokyo), 100 U/ml penicillin, and
100 mg/ml streptomycin (SigmaeAldrich Japan K.K., Tokyo.) at 37 C
with 5% CO2. Ca9-22 cells were grown in MEM containing 10% FBS,
100 U/ml penicillin,100 mg/ml streptomycin, and 4.1 mM glutamine
(Life Technologies Japan Ltd.) at 37 C with 5% CO2. HO-1-u-1 cells
were grown in D-MEM⁄F-12 (1) medium supplemented with 10%
FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin at 37 C with
5% CO2. All cells were maintained in 75 cm2 ﬂasks and plated into
96-well plates for subsequent experiments.
2.3. Cell growth in vitro
Each cell suspension (1000 cells/80 ml for HSC-2, HSC-3, and
Ca9-22, or 4000 cells/80 ml for HO-1-u-1) was placed into wells of a
96-well plate one day before experiments. On the next day, 80 ml of
rebamipide solution or medium (for the control group) was added
into each well (ﬁnal concentrations of rebamipide: 0.1e1000 mM),
and cells were cultured for another 3 days. Cell growth was
assessed with an in vitro toxicology assay kit based on sulforhod-
amine B (SigmaeAldrich Japan) according to the manufacturer's
instructions except for changes in wavelength. In brief, cells ﬁxed
with 10% trichloroacetic acid were stained with 0.4% sulforhod-
amine B solution and then washed with 1% of acetic acid before air
drying. The ﬂuorescence intensity (FI) of the dye in solution pre-
pared by adding 10 mM tris base solution was measured with a
microplate reader (Inﬁnite M1000, TECAN Japan Co., Ltd., Kawa-
saki) at ex/em ¼ 488/585 nm.
Cell growth rate (%) was calculated by the following formula:
Cell growth rate ð%Þ¼ ðRebamipide FI 585Blank FI 585ÞðControl FI 585BlankFI 585Þ 100
where Rebamipide FI 585 and Blank FI 585 represent FI of Reba-
mipide containing well and FI of Blank group, respectively. Control
FI 585 indicates FI of Control well.2.4. Animals
Seven to eight-week-old female Balb/c-nu/nu mice were pur-
chased from CLEA Japan Inc. (Tokyo) and were acclimated for more
than ﬁve days prior to experiments. The animals were maintained
on a 12 h lightedark cycle with free access to a sterilized pellet diet
(CRF-1, Oriental Yeast Co., Ltd., Osaka) and ﬁltrated water ad libitum
under speciﬁc-pathogen-free (SPF) conditions. The care and
handling of the animals were in accordance with the Guidelines for
Animal Care and Use of Otsuka Pharmaceutical Co., Ltd.
2.5. Tumor transplantation
Animals were lightly anesthetized with inhaled isoﬂurane gas,
and a cell suspension of 0.05 ml HSC-2 cells (2.0  106 cells) was
subcutaneously injected into the right femur using insulin syringes
(Terumo Co., Tokyo) for radiotherapy or 0.1 ml HSC-2 cells
(2.0  106 cells) was subcutaneously inoculated into the right ﬂank
with a tuberculin syringe (Terumo) with 27-G needles (Nipro Co.,
Osaka) for chemotherapy.
2.6. Tumor measurement
Tumor length (long diameter) and width (short diameter) were
measured to calculate tumor volume (TV) using an electronic
caliper at four or ﬁve time points throughout the experiments. TV
was calculated by the following formula:
TV mm3
 
¼ long diameter; mmð Þ  short diameter; mmð Þ2÷2
Relative tumor volume (RTV) was calculated on the basis of TV
by the following formula:
RTV ¼ ðTV on measurement dayÞðTV at group assignmentÞ
In addition to RTV, the tumor was isolated to measure tumor
weight (TW) on the last day of the experiments. The animals were
sacriﬁced by CO2 inhalation, and the tumor was excised. After
removal of adherent tissues, they were rinsed with saline, with
removal of excess water using a paper towel, and TW was
measured.
2.7. Group assignment
Tumor-bearing mice with TV of 150e300 mm3 with adjusted
shape were selected for group assignment (Day 0). Groups were
assigned by a stratiﬁed sequential randomization method based on
TV and body weight (BW) (weight coefﬁcient; TV: BW ¼ 4:1). The
animals excluded were sacriﬁced by CO2 inhalation.
2.8. Tumor growth in vivo
Micewere assigned to experimental groups: a vehicle group as a
control (n ¼ 8) and a rebamipide group (n ¼ 8). To evaluate the
effect of rebamipide on tumor growth in vivo, rebamipide was
administered twice a day (at approximately 9:00 and 17:00) from
Day 0 to Day 13 to mice with HSC-2 xenografted in the right ﬂank.
TV was measured at 5 time points throughout the experiment.
2.9. Radiotherapy and rebamipide administration
Mice were assigned into three groups of nine individuals. One
group did not receive X-ray irradiation, and the other two groups
were exposed to X-ray irradiation in combination with vehicle or
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an X-ray generator (CP-160 cabinet X-ray system, Faxitron Bioptics
LLC, Tucson, AZ, USA) at a dose of 2.5 Gy (dose rate:
0.817e0.828 Gy/min) as follows (22). The animals were lightly
anesthetized by inhalation of isoﬂurane gas and were immobilized
in an X-ray-shielded box (X-ray Irradiation Unit System, Hokkaido
System Science Co., Ltd., Sapporo). The right hind leg with xeno-
graft was pulled out of the box as shown in Fig. 1A and exposed to
X-ray irradiation on a rotating table (Fig. 1B) after awakening from
the anesthesia. Radiotherapy was administered once a day (at
approximately 10:30) from Day 0 to Day 4.
Vehicle (0.5% carboxymethyl cellulose sodium salt, CMC) and
rebamipide at a dose of 300 mg/kg (30 mg/ml suspended in 0.5%
CMC, 10 ml/kg) were orally administered twice a day (approxi-
mately 1 h before and 7 h after radiation) fromDay 0 to Day 4 to the
animals with an oral sonde (Fuchigami Kikai Ltd., Kyoto).
2.10. Chemotherapy and rebamipide administration
Mice were assigned to experimental groups, each comprising 8
mice: No treated group, a vehicle with chemotherapy group, and a
rebamipide with chemotherapy group. CDDP at a dose of 8 mg/kg
(16 ml/kg) or DOC at a dose of 15 mg/kg (10 ml/kg) was intrave-
nously administered once into the tail vein of the tumor-bearing
mice on Day 0 (at approximately 10:00). Vehicle and rebamipide
at 300 mg/kg were orally administered two times a day (at
approximately 9:00 and 17:00) from Day 0 to Day 4.
2.11. Determination of plasma concentration of rebamipide
Nude mice after single oral administration of rebamipide at
300 mg/kg were sacriﬁced at each time point (0.25, 0.5, 1, 2, 4, 8, 12,
and 24 h) under anesthesia with isoﬂurane gas. Three mice were
used for each time point. Blood (approximately 0.5 ml) was drawn
from the inferior vena cava with a heparinized syringe, transferred
to a tube, and cooled in ice cold water until centrifugation. Plasma
was obtained from the blood by centrifugation (1800 g, 10 min,
below 10 C). Plasma concentration of rebamipidewasmeasured by
liquid chromatographyeelectrospray ionization-tandem mass
spectrometry.
2.12. Statistical analysis
Cell proliferation was analyzed by two-way analysis of variance
with concentration and number of experiments as factors.Fig. 1. Representative photograph of HSC-2 tumor-bearing nude mice on the ﬁrst X-ray irra
(A) and exposed to X-ray irradiation on the rotating table (B).Statistical signiﬁcance was based on upper and lower 90% conﬁ-
dence levels.
To evaluate tumor growth in vivo, RTV and TW were compared
using repeated measures ANOVA and unpaired t test (two-sided),
respectively, between the vehicle and rebamipide groups.
The antitumor effect of radiotherapy or chemotherapy on hu-
man oral cancer xenograft was ﬁrst conﬁrmed by comparing RTV
between the no treated and radiotherapy or chemotherapy group
using repeated measures ANOVA. In addition to RTV, the antitumor
effect was evaluated by comparing TW between the groups by
unpaired t test (two-sided). After the efﬁcacy of the radiotherapy or
chemotherapy was conﬁrmed, the inﬂuence of rebamipide was
evaluated by comparing RTV and TW using repeated measures
ANOVA and unpaired t-test (two-sided), respectively, between the
radiotherapy or chemotherapy and radiotherapy or chemotherapy
plus rebamipide groups. Statistically signiﬁcant differences were
concluded at P < 0.05. Statistical analysis was performed with SAS
software release 9.1 (SAS Institute Japan Ltd., Tokyo).3. Results
3.1. Tumor cell growth in vitro and in vivo
We ﬁrst investigated whether rebamipide inﬂuenced cell
growth in vitro using four human oral squamous carcinoma cell
lines; HSC-2, HSC-3, Ca9-22, and HO-1-u-1. After seeding cells,
rebamipide (0.1e1000 mM) was added into the culture medium on
the next day, and cells were cultured for another 3 days. All four cell
lines linearly proliferated during the culture period (data not
shown). As shown in Table 1, lower and upper 90% conﬁdence limits
of cell growth rates in the rebamipide-treated groups fell within
90%e110% in all cell lines compared with those in the control
groups, indicating that rebamipide has no signiﬁcant effect on the
cell growth rates of these human oral squamous carcinoma cell
lines in vitro.
Next, we evaluated the effect of rebamipide on tumor growth in
HSC-2 tumor-bearing mice. Because only tumor HSC-2 cells, sub-
cutaneously injected into the right ﬂank, showed stable tumori-
genicity in a reproducible manner (data not shown), we selected
these cells for in vivo studies. We measured tumor diameter for
calculating TV for up to 14 days after initial administration of
vehicle or rebamipide for determining the effect of rebamipide on
tumor growth in vivo. As a result, there were no signiﬁcant differ-
ences in RTV and TW between the control and rebamipide groups
(Fig. 2), conﬁrming that rebamipide had no inﬂuence on tumordiation day. The right hind leg with xenograft was pulled out of the X-ray-shielded box
Table 1
Inﬂuence of rebamipide on cell growth of HSC-2, HSC-3, Ca9-22, and HO-1-u-1
in vitro.
Cell lines Concentration of
rebamipide (mM)
Cell growth rate
Average (%) 90% conﬁdence limits (%)
Lower Upper
HSC-2 0.1 99.5 98.8 100.2
1.0 99.6 98.9 100.3
10 100.0 99.3 100.6
100 102.0 101.3 102.7
1000 101.4 100.7 102.1
HSC-3 0.1 100.3 99.2 101.4
1.0 100.9 99.8 102.0
10 101.0 99.9 102.2
100 103.8 102.7 104.9
1000 101.9 100.8 103.0
Ca9-22 0.1 99.3 98.1 100.5
1.0 100.0 98.8 101.2
10 100.6 99.4 101.8
100 102.5 101.3 103.6
1000 104.2 103.0 105.4
HO-1-u-1 0.1 98.9 98.2 99.5
1.0 99.0 98.3 99.7
10 98.9 98.3 99.6
100 99.2 98.5 99.8
1000 101.2 100.5 101.8
Carcinoma cells were inoculated in 96-well plates (1000 cells/80 ml for HSC-2, HSC-
3, and Ca9-22 or 4000 cells/80 ml for HO-1-u-1). On the next day, 80 ml of the me-
dium with or without rebamipide was added into each well (ﬁnal concentrations of
rebamipide were 0.1e1000 mM), and the plates were cultured for another 3 days.
Cell growth was assessed by sulforhodamine B assay. The average of the control
group was set as 100%. No statistically signiﬁcant differences were observed be-
tween the control and rebamipide-treated groups in any carcinoma cell line.
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almost constant throughout the experiment (Supplementary
Table 1).3.2. Inﬂuence of rebamipide on the antitumor effects of
radiotherapy in HSC-2 tumor-bearing nude mice
We attempted to determine the effective doses of irradiation for
radiotherapy administered to HSC-2 tumor-bearing nude mice. We
found that 2.5 Gy of X-rays markedly suppressed the increase inFig. 2. Inﬂuence of rebamipide on tumor growth in HSC-2 tumor-bearing nude mice. Mi
consecutively for 14 days from Day 0. (A) Tumor volume in the right ﬂank of each mouse w
Each point represents the mean ± SEM. Vehicle group vs. rebamipide group (NS, not signiﬁc
on Day 14 after measuring TV. Data represent mean ± SEM. Vehicle group vs. rebamipideRTV (Fig. 3A, P < 0.01), without any changes in BW (Supplementary
Table 2). Rebamipide administration in addition to radiotherapy
showed no signiﬁcant effect on RTV (Fig. 3A) or TW (Fig. 3B),
indicating that rebamipide did not interfere with radiotherapy in
HSC-2 tumor-bearing nude mice. BW changes in the X-ray/reba-
mipide group were similar to those in the X-ray/CMC group
(Supplementary Table 2).3.3. Inﬂuence of rebamipide on the antitumor effects of
chemotherapy in HSC-2 tumor-bearing nude mice
We used CDDP and DOC as anticancer drugs because CDDP and
DOC have been selected for chemoradiotherapy for patients with
head and neck cancer (23). The single dose of CDDP (8 mg/kg, i.v.)
markedly suppressed the increase in RTV in HSC-2 tumor-bearing
nude mice (Fig. 4A, P < 0.01). The dose of CDDP used in this study
appears to be optimal for evaluating the inﬂuence of rebamipide on
chemotherapy with CDDP, considering that no animals died
following CDDP treatment, despite a moderate and transient
decrease in BW (Supplementary Table 3). RTV of the CDDP/reba-
mipide group was slightly but signiﬁcantly smaller than that of the
CDDP/CMC group (Fig. 4A, P < 0.05). TW was also signiﬁcantly
reduced (by 20.2%) by rebamipide (Fig. 4B, P < 0.05). An image of
the excised tumors is shown in Fig. 5. Although rebamipide
enhanced the antitumor action of CDDP, administration led to no
signiﬁcant difference in BW change (Supplementary Table 3).
Similar to CDDP treatment, a single dose of DOC (15 mg/kg, i.v.)
signiﬁcantly inhibited the increase in RTV (Fig. 6A, P < 0.01). There
were no signiﬁcant differences in either RTV (Fig. 6A) or TW
(Fig. 6B) between the DOC/CMC and DOC/rebamipide groups. With
respect to BW, the DOC treatment led to no weight loss during the
experiment, and rebamipide showed no signiﬁcant effect on
change in BW (Supplementary Table 4).3.4. Plasma concentration of rebamipide in nude mice
Rebamipide was rapidly absorbed after single oral administra-
tion at a dose of 300 mg/kg to nude mice. The mean plasma con-
centration of rebamipide reached a Cmax of 2715 ng/ml, equivalent
to 7.32 mM, at 0.5 h and then declined with a t1/2 of 1.29 h. AUCt was
5160 ng h/ml.ce were orally administered vehicle (0.5% CMC, bid) or rebamipide (300 mg/kg, bid)
as measured on Days 4, 7, 11, and 14, and relative tumor volume (RTV) was calculated.
ant, group effect in repeated measures ANOVA). (B) Tumor weight (TW) was measured
group [NS, not signiﬁcant, unpaired t-test (two-sided)].
Fig. 3. Inﬂuence of rebamipide on antitumor effects of radiotherapy in HSC-2 tumor-bearing nude mice. Mice were locally X-ray irradiated (2.5 Gy) consecutively for 5 days from
Day 0 and treated with oral vehicle (0.5% CMC, bid) or rebamipide (300 mg/kg, bid) consecutively for 5 days from Day 0. (A) Tumor volume in the right hind leg of each mouse was
measured on Days 4, 8, and 11, and relative tumor volume (RTV) was calculated. Each point represents the mean ± SEM. No-treated group vs. X-ray-treated group (**p < 0.01, group
effect in repeated measures ANOVA). X-ray-treated group vs. X-ray/rebamipide-treated group (NS, not signiﬁcant, group effect in repeated measures ANOVA). (B) Tumor weight
(TW) was measured on Day 11 after measuring TV. Data represent mean ± SEM. No-treated group vs. X-ray-treated group [**p < 0.01, unpaired t-test (two-sided)]. X-ray-treated
group vs. X-ray/rebamipide-treated group [NS, not signiﬁcant, unpaired t-test (two-sided)].
Fig. 4. Inﬂuence of rebamipide on the antitumor effects of chemotherapy with CDDP in HSC-2 tumor-bearing nude mice. Mice were treated with intravenous CDDP (8 mg/kg) on
Day 0 only and were orally administered vehicle (0.5% CMC, bid) or rebamipide (300 mg/kg, bid) consecutively for 5 days from Day 0. (A) Tumor volume in the right ﬂank of each
mouse was measured on Days 4, 7, and 10, and relative tumor volume (RTV) was calculated. Each point represents mean ± SEM. No-treated group vs. CDDP-treated group
(**p < 0.01, group effect in repeated measures ANOVA). CDDP-treated group vs. CDDP/rebamipide-treated group (#p < 0.05, group effect in repeated measures ANOVA). (B) Tumor
weight (TW) was measured on Day 10 after measuring TV. Data represent mean ± SEM. No-treated group vs. CDDP-treated group [**p < 0.01, unpaired t-test (two-sided)]. CDDP-
treated group vs. CDDP/rebamipide-treated group [#p < 0.05, unpaired t-test (two-sided)].
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Most patients with cancer who undergo chemotherapy and/or
radiotherapy experience adverse effects, such as nausea, vomiting,
diarrhea, fatigue, and oral mucositis (24). Oral mucositis inﬂuences
quality of life because of severe pain, leading to an impaired
nutritional status and risk of infection (16). However, efﬁcacious
preventive or therapeutic medications remain unestablished (17).
Rebamipide, a gastroprotective agent, has diverse biological effects,
including elimination of ROS via inhibition of superoxide anion
radical production (7, 8) and scavenging hydroxyl radicals (9, 10),
upregulation of growth factors such as epidermal growth and he-
patocyte growth factors and their receptors (13, 14), and inhibition
of the production of inﬂammatory cytokines and chemokines
(25e29). Although the precise mechanisms of oral mucositis
associated with radiotherapy and chemotherapy remain unclear,
they include production of ROS, upregulation of signal transductionof growth factors, and increase in pro-inﬂammatory cytokines and
chemokines (18, 30, 31), suggesting that rebamipide is useful for
treatment and prevention of oral mucositis. A preventive effect of
rebamipide gargle on chemoradiotherapy-induced oral mucositis
in patients with oral ulcer has recently been reported in a pilot
placebo-controlled study (19). However, rebamipide may interfere
with the antitumor effects of radiotherapy and chemotherapy by
elimination of ROS and upregulation of signal transduction of
growth factors.
To our knowledge, the present is the ﬁrst to report that reba-
mipide does not inﬂuence tumor growth of human oral squamous
carcinoma cells either in vitro or in vivo. Rebamipide showed no
signiﬁcant effect on tumor growth in four cell lines: HSC-2, HSC-3,
Ca9-22, and HO-1-u-1 at concentrations from 0.1 to 1000 mM
(Table 1). In contrast, several previous studies have indicated that
rebamipide inhibited cell growth of human gastric tumor cell lines
via downregulation of survivin and Aurora-B (32), upregulation of a
Fig. 5. Image of excised tumors in the experiment evaluating inﬂuences of rebamipide
on antitumor effects of chemotherapy with CDDP in HSC-2 tumor-bearing nude mice.
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phospholipase D (34, 35) in vitro. We have not investigated the
mechanism; however, this discrepancy in the effects of rebamipide
may depend on the differences in origin of human tumor cell lines
and/or the higher drug concentrations used in gastric tumor cell
lines studies (approximately 1e5 mM). In vivo, rebamipide at
300 mg/kg two times daily slightly suppressed tumor growth, but
the effect was not signiﬁcant in HSC-2 cell-bearing nude mice
(Fig. 2). Tsukamoto et al. have recently reported that rebamipide
prevented glandular stomach cancer and tended to suppress
invasive carcinoma in N-methyl-N0-nitro-N-nitrosoguanidine
(MNNG)-induced rat gastric carcinoma (36). They hypothesized
that ROS-scavenging activity of rebamipide is involved in attenu-
ation of MNNG-induced oxidative injury; however, serum con-
centrations of 8-oxo-20-deoxyguanosine, a marker of oxidative DNAFig. 6. Inﬂuences of rebamipide on antitumor effects of chemotherapy with DOC in HSC-2 t
0 only and were orally administered vehicle (0.5% CMC, bid) or rebamipide (300 mg/kg, bid)
was measured on Days 4, 7, and 10, and relative tumor volume (RTV) was calculated. Each po
effect in repeated measures ANOVA). DOC-treated group vs. DOC/rebamipide-treated group
was measured on Day 10 after measuring TV. Data represent mean ± SEM. No-treated group
DOC/rebamipide-treated group [NS, not signiﬁcant, unpaired t-test (two-sided)].damage, were not reduced by rebamipide. Rebamipide also did not
signiﬁcantly inhibit cell proliferation or induction of apoptosis in
cancerous lesions. Yamamichi et al. have suggested that signiﬁcant
increases in dendritic cells in precancerous gastric mucosa in
MNNG-exposed rats were associated with tumor-suppressive ef-
fects (37). Further studies are required for investigate the antitumor
effects of rebamipide.
To our knowledge, this is the ﬁrst report to evaluate the effect of
rebamipide on radiotherapy in tumor-bearing animals. To avoid
unnecessary exposure to irradiation, HSC-2 cells were inoculated in
the right femurs (Fig. 1A). This method is useful because no marked
BW loss was observed after irradiation (Supplementary Table 2). As
shown in Fig. 3A and B, 2.5 Gy of X-rays signiﬁcantly reduced the
growth of the tumor in HSC-2 cell-bearing nude mice. Rebamipide
slightly suppressed tumor growth, but the effect was not signiﬁ-
cant. It is believed that the tumor-suppressive effect of radiation is
in part dependent on generation of ROS, which causes DNA strand
breakage and induces cancer cell apoptosis (38, 39). Although
rebamipide inhibits superoxide anion radical production from
activated neutrophils and directly scavenges hydroxyl radicals, it
did not interfere with the antitumor effect of radiotherapy in our
study. We believe that the phenomenon can be explained by the
pharmacokinetics of rebamipide. To eliminate ROS, a rebamipide
concentration of 0.1 mM or higher is required (7e10,40e42).
However, the Cmax and AUC values of rebamipide in plasma were
2715 ng/ml, equivalent to approximately 7 mM, and 5160 ng h/ml,
respectively, after single oral administration of rebamipide at
300 mg/kg to the nude mice.
When rebamipide was orally administered at 100 mg to
humans, the serum concentration reached a Cmax of 280 ng/ml and
AUC0e6 h was 870 ng h/ml (43). The Cmax in nude mice was
approximately 10-fold higher than that measured following oral
administration of rebamipide to humans (43). The predicted AUC of
10.32 mg h/ml of 600 mg/kg/day rebamipide bid in nude mice was
approximately 4-fold higher than the predicted value of 2.61 mg h/
ml of 300 mg/kg/day rebamipide tid in humans (43). We concluded
that the plasma concentration and AUC of rebamipide in this study
were sufﬁciently high for comparison with clinical concentrations.
Intravenous DOC at 15 mg/kg signiﬁcantly inhibited tumor cell
growth (Fig. 6A and B). Rebamipide slightly suppressed tumorumor-bearing nude mice. Mice were treated with intravenous DOC (15 mg/kg) on Day
consecutively for 5 days from Day 0. (A) Tumor volume in the right ﬂank of each mouse
int represents mean ± SEM. No-treated group vs. DOC-treated group (**p < 0.01, group
(NS, not signiﬁcant, group effect in repeated measures ANOVA). (B) Tumor weight (TW)
vs. DOC-treated group [**p < 0.01, unpaired t-test (two-sided)]. DOC-treated group vs.
M. Shibamori et al. / Journal of Pharmacological Sciences 129 (2015) 18e2524growth, but the effect was not signiﬁcant. Intravenous CDDP at
8 mg/kg also signiﬁcantly inhibited tumor cell growth (Fig. 4A and
B). Rebamipide slightly but signiﬁcantly enhanced the antitumor
effect of CDDP in HSC-2 tumor-bearing nude mice. However,
because this study did not include a rebamipide-alone group, it was
unknownwhether this effect was synergistic or additive. Saad et al.
reported that intraperitoneal administration of rebamipide pro-
tected the rat kidney against nephrotoxic effects of CDDP via free
radical scavenging activity (44). It is difﬁcult to apply their ﬁndings
to our results because free radical scavenging activity may reduce
the antitumor effects of CDDP and the plasma concentration of
rebamipide is higher following parenteral administration than oral
dosing (data not shown). Because the reduction rate of TW by
rebamipide concomitant with CDDP therapy was only 20.2%, we
must carefully consider the signiﬁcance.
In conclusion, rebamipide treatments showed neither inﬂuence
on tumor growth nor interference with antitumor effects of
radiotherapy or chemotherapy with CDDP or DOC on human oral
squamous carcinoma.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2015.07.022.References
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